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Endothelial precursorsVascular diseases are increasing health problems affecting N25 million individuals inwesternized societies. Such
patients could beneﬁt from transplantation of tissue-engineered vascular grafts using autologous cells. One chal-
lenge that has limited this development is the need for cell isolation, and risks associated with ex vivo expanded
stem cells. Herewe demonstrate a novel approach to generate transplantable vascular grafts using decellularized
allogeneic vascular scaffolds, repopulatedwith peripheral whole blood (PWB) in vitro in a bioreactor. Circulating,
VEGFR-2+/CD45+ and a smaller fraction of VEGFR-2+/CD14+ cells contributed to repopulation of the graft.
SEMmicrographs showed ﬂat cells on the luminal surface of the grafts consistent with endothelial cells. For clin-
ical validation, two autologous PWB tissue-engineered vein conduitswere prepared and successfully used for by-
pass procedures in two pediatric patients. These results provide a proof of principle for the generation of trans-
plantable vascular grafts using a simple autologous blood sample, making it clinically feasible globally.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Vascular diseases have been documented to be key components of
the global burden of non-communicable diseases. Venous disease of
the lower extremities is very common, affecting∼25% of adults inwest-
ernized societies (Graham et al., 2003). Peripheral arterial disease is es-
timated to affect N25 million patients in Europe and North America
alone (Fowkes et al., 1991). These pathological conditions represent
an enormous burden, to both patients and healthcare systems. With an
aging population, expenditure in the treatment of such diseases is likely
to increase signiﬁcantly over the next 20 years (Raval and Losordo,
2013). Surgical replacement of damaged vessels may include the use of
autologous vessels, synthetic grafts such as Dacron or Gore-Tex, or
even allogeneic vessels from organ donors. Problemswith these alterna-
tives include stenosis, thromboembolization, calcium deposition, infec-
tion, the lack of autologous vessels of the proper phenotype or quality,
poor patency, donor shortage and the risk of alloimmunization or side
effects of immunosuppressive treatment (Veith et al., 1979; O'Donnell
et al., 1984; Kurobe et al., 2012). A possible intervention can be replace-
mentwith tissue-engineered blood vessels from allogeneic or xenogeneicion and Regenerative Medicine,
S-413 46 Gothenburg, Sweden.
Sumitran-Holgersson).
authorship.
. This is an open access article undersources, inwhich the donor's blood vessel is decellularized (DC) and used
as scaffold to repopulate with recipient's autologous stem cells. This ap-
proachwouldmake it possible to produce a vessel of the right phenotype
and obviate the need for life-long immunosuppression (Olausson et al.,
2012).
Studies have demonstrated that unseededDacron or Gore-Tex grafts
are incorporated in the host blood vessels through a process which is
generally referred to as graft healing resulting in endothelialization of
the synthetic graft (Pasquinelli et al., 1990). Endothelialization can
occur from blood vessel stems at either anastomosis. However, in
humans, endothelial cell (EC) ingrowth is very limited, that is, a fewmil-
limeters in years (Guidoin et al., 1993). Anothermechanism of endothe-
lial healing is, EC coming from circulating cells (Shi et al., 1994; Onuki
et al., 1997; Graham et al., 1980; Clowes et al., 1986; Poole-Warren
et al., 1996).We and others have shown that circulating ECs, endothelial
progenitor cells including themyeloid/monocytic lineages contribute to
re-endothelialization (Nowak et al., 2004; Asahara et al., 1997; Bailey
et al., 2006). Furthermore, progenitor cells for smooth muscle cells
(SMCs) are also present in circulating blood (Simper et al., 2002).
In contrast to experimental animals, the ﬂow surface of synthetic
vascular grafts remains unhealed in humans, particularly in the small
caliber conduits. Marked differences in graft healing exist between ani-
mals andman; and the usualmechanisms of graft endothelialization are
partially ineffective in man (Pasquinelli et al., 1990). It has been shown
that EC seeding of synthetic grafts prior to implantation has improvedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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et al., 1993; Deutsch et al., 2009). Strategies for repopulation of vascular
conduits have usually used in vitro expanded cells derived from bone-
marrow or peripheral blood. Recently, we successfully transplanted a
tissue engineered allogeneic vein with in vitro expanded autologous
bone-marrow derived stem cells. The tissue-engineered graft showed
good patency in vivo, thus proving a promising and safe clinical ap-
proach (Olausson et al., 2012). However, the disadvantage with this ap-
proach is that the collection, isolation and large scale expansion of stem
cells from tissues or bone-marrow in a limited timewith low variability
is highly challenging.
All these observations led us to hypothesize that the use of peripher-
al whole blood (known to contain circulating ECs/endothelial progeni-
tor cells (EPCs)) would result in efﬁcient recellularization (RC) and
endothelialization of acellular veins, without the need to isolate and ex-
pand subpopulations of angiogenic progenitor cells from bone-marrow
or whole blood. Furthermore, an in vitro complete and preformed endo-
thelial lining at the time of implantation would help to increase the pa-
tency of these engineered vein grafts. Thus,we aimed to develop an easy
procedure that would increase the clinical use of the technique and
make it globally accessible. We report the clinical transplantation of
tissue-engineered allogeneic veins using autologous peripheral whole
blood (APWB), in two pediatric patients with portal vein thrombosis.
2. Materials and Methods
All research protocols were approved by the Swedish institutional
review boards and ethics committees.
2.1. Decellularization of Veins
Human iliac or mammary veins about 7–9 cm were retrieved from
14deceased organdonors after informed consent from the relatives, im-
mediately stored in sterile phosphate buffered saline (PBS) containing
1% penicillin, streptomycin, amphotericin B and transported to the lab-
oratory. On an average, the outer diameter of iliac veins used in the pro-
cedures ranged between 1.5 and 2 cmandmammary veins ranged from
0.3–0.7 cm. Decellularization (DC) was carried out as described by us
earlier (Olausson et al., 2012) using 1% Triton X-100 and 1% tri-n-butyl
phosphate (TNBP) and 4 mg/L DNAse under sterile conditions.
2.2. Characterization of Decellularized Veins
At the end of the DC process, biopsies were taken from decellularized
veins (DV) and processed histologically with Hematoxylin–Eosin (HE),
Masson's Trichrome (MT) and Verhoeff Van Gieson (VVG) staining,
DNA quantiﬁcation, Luminex®, scanning and transmission electron mi-
croscopic analysis, tensile strength and extracellular matrix (ECM) quan-
tiﬁcations. Please see Supplement 1 for further details.
2.3. Recellularization of Veins
The entire RC processwas performed under sterile conditions and all
perfusions were carried out in an incubator at 37 °C supplied with 5%
CO2. Before RC, the veins were perfused with heparin (Leopharma,
Sweden) at a concentration of 50 IU/ml PBS for 2 h. The heparin was
drained off and the whole blood was immediately perfused for 48 h at
2 ml/min speed. For collection of blood, see Supplement 1. The blood
was then drained off and the veins were washed with PBS containing
1% penicillin–streptomycin–amphotericin for 3–5 min or until the blood
was completely removed. The veins were subsequently perfused 4 days
with EC and 4 dayswith SMCmedia. The complete ECmedium contained
basal medium MCDB 131, 10% heat inactivated human AB serum, 1% L-
glutamine and 1% penicillin–streptomycin–amphotericin and supple-
mented with EGM-2 Single Quote kit (Lonza, Walkersville, MD USA). A
commercially available SMC medium (Cascade Biologics) containinggrowth and differentiation factor supplements was used. The veins
were recellularized for a total of 10 days.
2.4. Characterization of Recellularized Veins
To visualize the presence of EC, antibodies to CD31 (1:1000)
(Abcam, Germany) and von Willebrand factor (1:100) (Santa Cruz,
Germany) were selected and stained by immunoﬂuorescence, while
smooth muscle actin (1:50) (Abcam, Germany) to visualize SMC. The
tensile strength of recellularized veins (n = 3), work and elongation
was compared to normal and decellularized veins.
2.5. Enumeration of Cells in the Repopulated Veins
Quantiﬁcation of cell numbers in the lumenwas done by staining for
the endothelial cell marker VEGFR-2 and monocyte marker CD14.
Single and double-positive cells were quantiﬁed manually. On average,
15 images of the lumen were taken per vein covering an area of
47500 μm2. The data is represented as the number of cells per square
centimeter area of the vein and the values are represented with stan-
dard error mean of the original value.
2.6. Clinical Transplantations
2.6.1. Patient 1
A 4-year-old girl was referred to the children's hospital in Goth-
enburg after a history of fatigue, a slightly elevated body temperature
and a tender tumor in the left upper abdominal quadrant present
since 1 month of age. Initial tests at 4 years showed anemia, thrombo-
cytopenia, and neutropenia. A CT-angiography showed no portal circu-
lation from the superior mesenteric vein to the liver (Fig. 4F) and
problems in detecting the intrahepatic portal vascular system. The um-
bilical veinwas not open and the jugular veinswere estimated to be too
short as the only source of vein graft (also see surgical procedure and
post-operative monitoring in the Supplement methods section).
Splenomegaly and cavernous vein formation was found in the hilum.
An endoscopy demonstrated esophagus varices from 15 to 25 cm
down to the cardiac region. The child was evaluated for a possible
Mesorex procedure by a pediatric multidisciplinary team. The child
weighed 17 kg and was 107 cm in height.
2.6.2. Patient 2
A 24-month-old girl, weighing 7.4 kg, was referred to the children's
hospital with a history of upper abdominal pain coincidingwith feeding
of the child, starting at 8months after birth. Initial investigation at a local
hospital found splenomegaly and pancytopenia. A hematological work
up was done and found normal. A CT-angiography revealed the absence
of the portal vein and difﬁculties with detection of any intrahepatic por-
tal vascular system (Fig. 4G). No patent umbilical vein could be detected.
Endoscopy showed prominent varices explaining the pain correlating to
food intake. The childwas evaluated for a possibleMesorex procedure by
a pediatric multidisciplinary team. The child weighed 7.4 kg and was
73.5 cm in height.
Since no suitable autologous veins were detected in both the pa-
tients, two decellularized veins were recellularized under good man-
agement practice (GMP) facilities available at The Sahlgrenska
University Hospital-Gothenburg-Sweden as described above with
25 ml autologous blood taken from the two patients and used for the
Mesorex procedures.
2.6.3. The Ethical Process
As in the previous published case (Poole-Warren et al., 1996) in the
present two cases, a pediatric team performed the evaluation in a mul-
tidisciplinary fashion, which also includes abiding to the UNICEF Con-
vention on the Rights of the Child. The parents were informed several
times and given details of the procedure, the possible anticipated
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rection of the EHPVO. This information was given to the parents by
the responsible surgeon together with members of the pediatric team.
The parents also provided informed consent, whichwas given to the pe-
diatric team in the absence of the operating surgeon to avoid pressure.
Moreover, permissions from the two regulatory bodies in Sweden—
The National Medical Board and The Medical Products Agency were
granted. Permission from members of The Local Ethical Board (Etisk
Forum)was also obtained prior to proceeding with the transplantation.
Please see Supplement 1 for post-transplant monitoring and statistics.3. Results
3.1. Decellularized Veins and Extracellular Matrix
Nine cycles of decellularization with 1% Triton and 1% tri-n-butyl
phosphate resulted in generation of pale and translucent veins (Supple-
ment Fig. S1A, DV). The veins were successfully decellularized in
12 days as evidenced by lack of nuclei when compared to normals
(Fig. 1A–C, also see Supplement Fig. S1B–E) and conﬁrmed by electron
microscopy (Supplement Fig. S1F–H).Major ECMproteins such as colla-
gen I, collagen IV, ﬁbronectin and laminin (Fig. 1D) were preserved in
DV. The quantity of GAGs (p = 0.041) but not collagen (p = 0.700)
was signiﬁcantly decreased in veins after DC (Supplement Fig. S2A). A
signiﬁcant decrease in DNA concentration was found in DV (15.5 ±
7.93 ng/mg) as compared to 244.5 ± 65.01 ng/mg of tissue in normal
veins (p= 0.007). Several growth factors albeit lowerwere still present
in the DV (Supplement Fig. S2B). Tensile strength testing of the DC veins
showed a decrease in thework needed to deform the samples completely
when compared to normal samples and the elongation measured at 50%Fig. 1. A representative microscopic view of decellularized vein grafts. Masson's Trichrome stai
smooth muscle cells, but with abundant collagen still present (blue) and (B) normal vein s
(C) Negative controls. (D) Immunohistochemical staining of normal and DV for the various ext
though no cells/nuclei are seen, the ECM components stained positive indicating the retainmeof total work had signiﬁcantly decreased after DC (p b 0.05, Supplement
Fig. S2C & D).
3.2. Recellularization of Veins
The grossmorphology of veins after RC looked pinkishwith good tu-
nica externa (Supplement Fig. S1A, RV). Histological examination two
days after perfusion of DV with whole peripheral blood showed migra-
tion of cells into the tissue, (Fig. 2A). Four-day perfusion with EC medi-
um resulted in an almost conﬂuent monolayer of cells on the lumen of
the vein (Fig. 2B) and immigrated cells in themedia (Fig. 2C). This is ev-
idenced by single immunoﬂuorescent staining for CD31 (Supplement
Fig. S3E) and alpha smoothmuscle actin (Supplement Fig. S3D) staining.
VVG and MT staining of the veins also conﬁrmed the presence of nuclei
(black), cytoplasm (red in MT) and collagen (red in VVG and blue in
MT) (Fig. 2D & E respectively).
Phenotypic characterization of the peripheral blood cells involved in
formation of neo-endothelialization demonstrated that many cells
expressed the tyrosine kinase receptor-vascular endothelial growth fac-
tor receptor-2 (VEGFR-2) (Fig. 3A; after blood & B; after endothelial cell
medium). Negative controls are shown in Supplement Fig. S3A–C. Cells
positive for the leukocyte common antigen CD45 were found mainly in
the adventitia and not the lumen of the veins (Fig. 3C), indicating that
these cells mainly differentiated to smooth muscle cells as evidenced
by positive staining for alpha smooth muscle cell actin. A smaller frac-
tion of CD14+ cells (green, Fig. 3D) which also stained positive for
VEGFR-2 (red, yellow indicates co-localization; arrows) contributed to
this process (Fig. 3E). A continuousmonolayer of endothelial cells stain-
ing positive for VEGFR-2 and the EC marker CD31 (arrows) was ob-
served after 4 days with EC medium (Fig. 3F). These ﬁndings were
corroborated by scanning electron microscopy (Fig. 4A–C) which alsoning of (A) decellularized vein (DV) showing no nuclei, indicating lack of endothelial and
howing presence of nuclei (black, arrows), cytoplasm (red/pink) and collagen (blue).
racellular matrix components. Nuclei are seen only in normal but not in DV. In the DV al-
nt of important ECM proteins (n = 14). A–D: Scale bar = 75 μm.
Fig. 2.Microscopic view of a representative bioengineered vein graft with peripheral whole blood. (A) Picture showsmigration of cells (black) into the tissue after perfusion with
blood, (B & C) presence of an endothelial cell monolayer on the luminal side after perfusion with endothelial cell medium and an overall improved architecture of the vein. Staining of
tissue-engineered human veins recellularized with peripheral whole blood by (D) Verhoeff Van Gieson, showed presence of nuclei (black) for endothelial (black arrows) and smooth
muscle cells (yellow arrows). The cytoplasm was stained pink and elastin black. (E) Masson's Trichrome staining showed presence of black nuclei (black), blue collagen and pink cyto-
plasm (n = 5). A–C: Scale bar = 75 μm, D & E: scale bar = 25 μm.
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veins consistentwith endothelial cells (Fig. 4D). The cells were negative
for the markers CD3, CD19, CD68, CD133, CD34, CD56 and CD61, indi-
cating that the major cell types contributing to repopulation are
VEGFR-2+/CD45+ and VEGFR-2+/CD14+ cells.
Our initial results showed no difference in the numbers of cells at
6 days and 10 days, therefore enumeration data is presented at two
time points i.e. immediately after perfusion with blood (48 h) and
after perfusionwith ECmedium for four days (total 6 days). On an aver-
age, we found 11.5 ± 0.02 × 104 DAPI + cells/cm2 in the lumen of
normal control veins. In the recellularized veins, staining for VEGFR-2
after perfusion with whole blood demonstrated an average of 5.93 ±
1.26 × 104 cells/cm2. The numbers of VEGFR-2+ cells were increased
after perfusion with EC medium (7.65 ± 1.47 × 104 cells/cm2). This
was however not statistically signiﬁcant (p = 0.387). In addition, the
number of CD14+ cells after two days of perfusion with blood showed
an average of 1.11 ± 0.32 × 104 cells/cm2, and the numbers of these
cells were also not signiﬁcantly increased after perfusion with EC medi-
um (2.63 ± 0.70 × 104 cells/cm2, p = 0.132). Double staining of the
cells in the lumen for CD14 and VEGFR-2 revealed that approximately
half of the CD14+ cells also expressed VEGFR-2 (Fig. 4E) (0.71 ± 0.22
× 104 cells/cm2 with blood and 1.39 ± 0.37 × 104 cells/cm2 after EC
medium).
Sterility testing showed no marked increase in absorbance during
14 days ofmedia culture. The average of optical densities at 600 nmmea-
sured in spectrophotometer for freshmedia (0.006) was similar to that of
perfused media (0.009) and not signiﬁcantly different (p = 0.251). The
average values for negative control and positive control are 0.010 and
0.36 respectively. Nomicrobial colonieswere seen on the agar plates. Bio-
mechanical analyses showed that the work increased signiﬁcantly afterRC while no signiﬁcant changes were seen in the elongation between
RC and DC samples (Fig. S2C & D). No signiﬁcant difference was found
between normal and RC samples, indicating that the biomechanical prop-
erties of the RC veins are similar to the native veins (Supplement Fig. S2C
& D).
3.3. Clinical Cases
To test the in vivo patency of these tissue-engineered veins, two
pediatric patients suffering with extra hepatic portal vein obstruction
(EHPVO) were transplanted with tissue engineered veins regenerated
using 25 ml autologous peripheral blood on compassionate basis.
Fig. 4F shows a CT-angiography demonstrating no portal circulation
from the superior mesenteric vein to the liver and problems in de-
tecting the intrahepatic portal vascular system in patient 1. Similarly,
Fig. 4G shows a CT-angiography demonstrating the absence of the
portal vein and difﬁculties with detection of any intrahepatic portal
vascular system in patient 2.
3.4. Clinical Transplantation Data
Patient 1 received an 8 cm long vein, anastomosed to the superior
mesenteric vein and the left portal vein as earlier described (Fig. 5A)
Olausson et al., 2012. The central venous pressure (CVP) was 11 cm
H2O and the portal pressure dropped from 22 cm to 14 cm after re-
perfusion of the vein— a difference of 3 cm compared to the pressure
in the right atrium. The ﬂow velocity showed 30–40 cm/s both in the
portal vein and hepatic artery (Fig. 5B). Twenty-one months post-
transplantation the patient has an unchanged image as seen in a 3D re-
construction of the graft (see Video in Supplement). The esophageal
Fig. 3. Phenotypic labeling of peripheral whole blood cells involved in repopulation of the bioengineered veins. (A) Cells staining positive (brown) for the tyrosine kinase receptor VEGFR-2
are found adhering to the lumen of the scaffold after perfusion of peripheral blood for 48 h. (B) These VEGFR-2+ cells formed a monolayer on the luminal side of the bioengineered vein
after perfusion of endothelial cellmedium for 4 days (brown). (C) Cells expressing the common leucocytemarker CD45were foundmainly in themedia and adventitia (arrows). (D & E)A
small fraction of cells in the lumen also stain positive for the monocyte marker CD14 (green), while double staining showed that some were also double positive (arrows) for VEGFR-2
(red). (F) Double staining showing that VEGFR-2+ cells were also positive for the endothelial marker CD31. Yellow color indicates co-localization of the two markers. The repopulating
cells were negative for other markers such as CD3, CD19, CD68, CD133, CD34, CD56 and CD61 (n = 6).
Fig. 4. Characterization of the recellularized veins and pre-transplant clinical data of the two patients. (A & B) Scanning electronmicrographs of the recellularized veins showing binding of
cells (arrows) to the lumen and in the media after perfusion with peripheral whole blood. (C & D) Further perfusion with endothelial cells medium resulted in formation of a continous
smooth endothelial cell layer (arrows). (E) Higher numbers of VEGFR-2+ cells were found in the recellularized veins (n=6) as compared to CD14+ cells both after perfusionwith blood
and endothelial cellmedium (EM). (F & G) CT-angiographs of patients 1 & 2 respectively before transplantation. (F) Patient 1: showing varicose veins in the hilum (blue) and at the esoph-
agus (black). (G) Patient 2: showing no intrahepatic portal system. In both cases, no portal circulation is observed.
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Fig. 5. Post-transplant clinical data for the two transplanted patients. (A) Patient 1: Postoperative CT-angiograph, showing the new graft (blue arrow) with good anastomotic sites (black
arrows) and well established intrahepatic portal system. (B) The postoperative period was uneventful with good intrahepatic blood ﬂows. The ﬂow velocity showed 30–40 cm/s both in
the portal vein and in the hepatic artery. (C) Patient 2: CT-angiography after ﬁrst transplantation, showing a revascularized portal ﬂow and intrahepatic portal system (blue arrow). At the
six-month checkup, the patient had a reduced diameter at both anastomotic sites, (black arrows), however the intrahepatic portal vein system was signiﬁcantly developed (D). Seven
months later the patient received a second graft. (E) CT angiography day after surgery of the second graft revealed poor perfusion of the right portal system. (F) However, after a percu-
taneous angiography the right portal system was well perfused.
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are normal. No surgical or other complications have been observed dur-
ing frequent regular controls and ultrasounds.
Patient 2 received a 6–7 cm long vein, initially anastomosed to
the patient's own 5 cm long umbilical vein. This had to be adjusted
perioperatively due to thrombosis in the umbilical vein section,
resulting in an anastomosis between the vein graft and the left portal
vein as earlier described (Olausson et al., 2012). The gradient between
the cava and the intrahepatic system was b1 cm H2O, indicating good
liver parenchyma, whereas the gradient between the portal vein and
the mesenteric system remained 6 cm, indicating a partial stricture.
On the second day after surgery the patient was revised due to a
narrowing at the site of anastomosis in the liver (Fig. 5C). After revision,
both anastomoses were patent, but difﬁculties to lower the difference
between the CVP and themesenteric pressure below8 cmH2Owere en-
countered. The postoperative period was otherwise uneventful with
good intrahepatic blood ﬂows. At the 6-month checkup, the patient
had a reduced diameter at both anastomotic sites, however the
intrahepatic portal vein system was signiﬁcantly developed (Fig. 5D).
An attempt to dilate the narrow anastomosis on themesenteric side re-
sulted in thrombosis of the graft. Sevenmonths after the ﬁrst procedure
a decision to revise the graft was taken and the patient received a sec-
ond vein, prepared exactly as the ﬁrst. During this procedure difﬁculties
to open up the right portal vascular bed was evident. The right portal
systemwas difﬁcult to reach with a surgical microprobe. After reperfu-
sion a remaining gradient of 10 cm H2O was detected. CT angiography
the day after the surgery revealed poor perfusion of the right portal sys-
tem (Fig. 5E). Four days later a percutaneous angiography was per-
formed with measurements of the gradient over the anastomoses. The
right portal system was now well perfused and the gradient was only
3 cm H2O (Fig. 5F). Further controls have been uneventful, (Nineteenmonths after the procedure). Both patients received heparin infusions
for 2 weeks followed by warfarin for 1 year as anti-coagulation
therapy.
For both patients INR improved from (1.6–1.8) prior to surgery to
(1.0–1.2) 2 weeks after surgery. This was similar to the experience pre-
viously reported in theﬁrst patient. Platelet count aswell as hemoglobin
and leucocytes also improved. At 1.5 years post-implantation, both pa-
tients are less tired and symptoms related to food intake for patient 2
disappeared after surgery. Furthermore, no antibodies to HLA class I or
II antigens were found. Patient 1 now weighs 20.3 kg and is 118.7 cm
long, while patient 2 weighs 10 kg and is 87 cm long.
4. Discussion
Our study is a proof-of-concept clinical report of the successful
recellularization of decellularized human blood vessels with autologous
peripheral whole blood, which were subsequently used for a bypass
procedure in two patients with portal vein thrombosis without the
need for immunosuppression. The work is important conceptually be-
cause it provides early evidence for generating clinically useful person-
alized blood vessels using a simple blood sample from the patient. The
work also establishes the feasibility and safety of a novel paradigm for
treatment, in cases of venous insufﬁciency, obstructed veins or inade-
quate autologous veins within a short period of time. This method of
recellularization is an easy procedure that will increase the clinical ap-
plication of the technique and make it globally feasible.
Recellularization using blood is advantageous over the use of in vitro
expanded autologous stem cells as onemay reduce the risk of spontane-
ous mutations that may be associated with expanded cells. One clinical
study (Hibino et al., 2010) reports successful outcomes in their thoracic
venous conduit using a bio-absorbable graft incubated for 2 h with an
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extended ex vivo culture. However, aspiration of bone-marrow is an in-
vasive technique, needing anesthesia and specialized personnel to per-
form the procedure and may also be associated with risk for infection.
The short incubation time with isolated cells will not permit the forma-
tion of an EC layer, which is a crucial factor for clinical patency, and func-
tion of the blood vessel. Our approach promises a simpliﬁed convenient
technique. We speculate that the ECM proteins and growth factors
retained in the tissues after DC may enhance the attachment and
growth of the recipient cells in the tissue (Li et al., 2004). At present,
the deﬁnition of EPC remains controversial and is not yet consistent
(Yoder and Ingram, 2009). Most commonly, marker combinations for
identifying the putative circulating EPC comprise certain hematopoietic
lineagemarkers, such as, CD133, CD34, VEGFR-2, Tie-2, andUEA-1 lectin
(Yoder and Ingram, 2009; Peichev et al., 2000) and circulating myeloid
cells expressing CD14 (Hristov et al., 2007; Venneri et al., 2007) —
corresponding to a heterogeneous cell population possessing an
overlapping phenotype with endothelial cells and hematopoietic pro-
genitors. PBMC are also capable of developing into ﬁbrocytes— potential
vascular progenitors (Bucala et al., 1994). Fibrocytes express the com-
mon leukocyte antigen CD45 and are variably reported to express
CD14 and CD34 (Medbury et al., 2008). These cells are also known to ex-
press collagen I and the alpha-smoothmuscle actin. In the present study,
phenotypic characterization of the cells from PWB repopulating the
veins demonstrated that the majority of the cells expressed VEGFR-2,
while a small fraction was also double positive for the monocyte marker
CD14 (VEGFR-2+/CD14+), indicating that the major cell types are de-
rived from the monocytic/macrophage lineage, conﬁrming results from
several published reports (Nowak et al., 2004; Asahara et al., 1997;
Bailey et al., 2006; Simper et al., 2002). Interestingly, cells that migrated
into the media were found to be CD45+which also stained positive for
the marker smooth muscle cell alpha actin, indicating that this cell pop-
ulation may include precursors of smooth muscle cells. Thus, regenera-
tion of blood vessels can attract a variety of endothelial and smooth
muscle cell precursors that may differentially express the VEGFR-2,
CD45 and CD14 receptors. Perfusion with endothelial cell medium, in-
creased, althoughnot signiﬁcantly, the numbers of VEGFR-2+cells, indi-
cating proliferation of these cells. We also observed the formation of a
complete ECmonolayer. Thus, perfusionwith PWB is themost important
step for endothelialization, since perfusionwith PWBwill permit binding
of many endothelial precursor cells, while perfusion with EC medium
(which contains VEGF and other growth factors) may help in prolifera-
tion and formation of an EC monolayer.
However, perfusionwith smoothmuscle cell mediumdid not signif-
icantly affect any of these parameters. As a consequence,we have decid-
ed to skip perfusion with SMC medium.
We have reported earlier that peripheral blood cells expressing the
tyrosine kinase receptors VEGFR-2 or Tie-2 deﬁne functionally compe-
tent cell populations capable of re-endothelialization anddifferentiation
into smooth muscle cells, the numbers of which are≈0.8% and 2% re-
spectively in PWB (Nowak et al., 2004). In the present study enumera-
tion of VEGFR-2+ cells after perfusion with 25 ml blood from various
donors showed an average cell count of 7.65 ± 1.47 × 104 cells/cm2 in
RV which was similar to the numbers reported by Ranjan AK et al.
who used 6.6 × 104 EPC for endothelialization of small diameter vascu-
lar prosthesis (Ranjan et al., 2009). The volume of 25 ml blood for
recellularization was chosen for the following two reasons, a) this was
the minimum amount required for perfusion through the vein and the
bioreactor system and b) consideration for pediatric patients with frag-
ile blood vessels. Larger volumes of blood did not result in reduced time
needed for repopulation (unpublished observations), although this
ﬁnding needs to be veriﬁed in a larger study.
In the present and other currently ongoing studies we have success-
fully recellularized veins using blood from individuals and patients in
the age range of 4–55 years. However, it is reported that the numbers
of circulating stem/precursor cells is decreased in patients with diabetes(van Ark et al., 2012) and end-stage renal diseases (Westerweel et al.,
2007). So it remains to be tested whether this method would work in
such patients. We did not detect any HLA antibodies after transplanta-
tion indicating satisfactory decellularization of the blood vessels. The
patients have been followed for one year and Nine months and one
year and Seven months respectively. Although patient 2 had to be
re-operated and problems with the anastomoses could be noted, this
was evident already at the primary operation. Small children or children
with inferior intrahepatic portal vein system may require sequential
surgery. The second intervention however, opened up of the obstructed
portal bed and diminished the initial gradient over the anastomosis.
Taking into account that the alternative treatment for these patients is
liver transplantation including lifelong immunosuppression, a revision
must be seen as a minor drawback.
Both patients have been transplanted on compassionate grounds
and therefore optimization of the technique has been on a “patient to
patient” basis. We are currently seeking permits to carry out a clinical
trial, which will include a larger number of patients to determine the
efﬁcacy of grafting tissue-engineered veins as vascular replacement
therapy.
The possibility of using peripheral blood to regenerate a decellularized
vessel is a major step towards making tissue-engineered blood vessels a
feasible technique globally for clinical application and our results prove
the clinical potential of thismethod in the treatment of patients with vas-
cular diseases.
In conclusion, the possibility of using peripheral blood to regenerate a
decellularized vessel is a major step towards making tissue-engineered
blood vessels a feasible technique globally for clinical application and
our results prove the clinical potential of this method in the treatment
of patients with vascular diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2014.09.001.
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